Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia

NCT04609865 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped departure of the principal investigator and inclusion difficulties

Conditions

Acute Respiratory Distress Syndrome (ARDS)
COVID-19
Corona Virus Infection

Interventions

DRUG: Lidocaine 2%
DRUG: Control

Sponsor

University Hospital, Strasbourg, France